arrow
S

Sara Manrique-Arija

Rheumatology Department
H指数:24
被引数:2,326

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Major adverse cardiovascular events in Sjögren’s disease: incidence, associated factors, and impact on mortality in a prospective multicenter cohort

干燥综合征患者主要心血管不良事件:发病率、相关因素及对死亡率的影响——一项前瞻性多中心队列研究

2026-06-010
PRE
Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry

类风湿关节炎患者使用生物制剂和靶向合成改善病情抗风湿药后的癌症风险:BIOBADASER III登记研究的结果

2025-11-010
PRE
High incidence of lymphoma in Sjögren’s disease: predictors and mortality implications in a prospective cohort study

舍格伦综合征中淋巴瘤的高发病率:前瞻性队列研究中的预测因素及死亡率影响

2025-08-060
PRE
Long-term changes in Sjögren’s disease: a 9-year prospective follow-up study from the SJOGRENSER Registry

干燥综合征的长期变化:一项来自SJOGRENSER登记注册的9年前瞻性随访研究

2025-06-170
PRE
Cancer risk in Sjogren's disease: A longitudinal cohort study on incidence, predictors, and mortality impact

干燥综合征中的癌症风险:一项关于发病率、预测因子和死亡率影响的前瞻性队列研究

2025-06-130
PRE
Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry

类风湿关节炎初治患者中使用生物制剂和靶向合成药物的临床及处方特征中的性别差异:来自BIOBADASER III登记研究的数据

2025-05-140
OA
Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis

肿瘤坏死因子抑制剂对炎症相关认知功能障碍的影响:一项前瞻性分析

2025-04-110
OA
Mortality in Patients With Sjögren Disease: A Prospective Cohort Study Identifying Key Predictors

干燥症患者的死亡率: 一项确定关键预测因素的前瞻性队列研究

2025-01-150
PRE
EVALUATION OF THE SURVIVAL AND SAFETY OF BIOLOGIC AND TARGETED SYNTHETIC DMARD IN PATIENTS WITH DIFFICULT-TO-TREAT RA USING DATA FROM THE BIOBADASER 3.0 REGISTRY

评估生物制剂和靶向合成DMARD在难治性RA患者中的生存与安全性:基于BIOBADASER 3.0登记研究的数据库分析

2024-06-010
PRE
GENDER DIFFERENCES IN CLINICAL AND PRESCRIBING CHARACTERISTICS OF BIOLOGIC AND TARGETED SYNTHETIC DRUGS IN NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS. DATA FROM BIOBADASER 3.0 REGISTRY

类风湿关节炎初治患者中生物制剂和靶向合成药物的临床及处方特征性别差异。数据来自BIOBADASER 3.0注册登记系统。

2024-06-010
PRE
Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry

皮下注射生物类似药肿瘤坏死因子抑制剂与原药的长期生存率比较: 多中心前瞻性注册结果

2024-06-010
OA
GENDER AS A KEY FACTOR OF DELAY IN PRESCRIBING THE FIRST BIOLOGIC OR TARGETED SYNTHETIC DRUG IN PATIENTS WITH RHEUMATOID ARTHRITIS. DATA FROM BIOBADASER 3.0 REGISTRY

性别作为延迟为类风湿关节炎患者首次处方生物制剂或靶向合成药物的关键因素。数据来源于BIOBADASER 3.0注册研究。

2024-06-010
PRE
SJOGRENSER REGISTRY: PROSPECTIVE EVALUATION OF A COHORT OF PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME AFTER 8 YEARS OF FOLLOW-UP

SjögrensRegistery:对原发性Sjögren综合征患者队列进行为期8年随访的前瞻性评估

2024-06-010
PRE
Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study
2024-03-282
OAAI